Compositions and methods of nucleic acid-targeting nucleic acids

Patent metadata

Field	Value
Publication number	US-2016046962-A1
Application number	US-201514749594-A
Country	US
Kind code	A1
Filing date	Jun 24, 2015
Priority date	Mar 14, 2013
Publication date	Feb 18, 2016
Grant date	—

Abstract

This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.

First claim

1 - 26 . (canceled)

27 . A composition comprising:
a modified Cas9 protein, wherein the modified Cas9 protein comprises a modification of a region of a wild-type Cas9 protein selected from the group consisting of a Cas9 bridge helix region; a Cas9 highly basic patch within the Cas9 N-terminal region; a Cas9 HNH domain region; a Cas9 RuvC domain region; a Cas9 P-domain recognition region; an added enzymatic activity; insertion, deletion or substitution of a domain; insertion, deletion or substitution of a structural motif; a fusion; and combinations thereof.

28 . The composition of claim 27 , wherein the wild-type Cas9 protein is a Streptococcus pyogenes Cas9 protein.

29 . The compositions of claim 27 , wherein the modification is in the region of the wild-type Cas9 protein corresponding to amino acids 1-270 of a Streptococcus pyogenes Cas9.

30 . The compositions of claim 29 , wherein the modification is in the region corresponding to amino acids 50-100 of a Streptococcus pyogenes Cas9.

31 . The compositions of claim 30 , wherein the modification is in the region corresponding to amino acids 65-95 of a Streptococcus pyogenes Cas9.

32 . The compositions of claim 29 , wherein the modification is in the region corresponding to amino acids 22-49 of a Streptococcus pyogenes Cas9.

33 . The compositions of claim 27 , wherein the modification is in the region corresponding to amino acids 551-556 of a Streptococcus pyogenes Cas9.

34 . The compositions of claim 27 , wherein the modification is in the region corresponding to amino acids 445-507 of a Streptococcus pyogenes Cas9.

35 . The compositions of claim 27 , wherein the modification is in the region corresponding to amino acids 860-1100 of a Streptococcus pyogenes Cas9.

36 . The compositions of claim 27 , wherein the modification is in the region corresponding to amino acids 1096-1225 of a Streptococcus pyogenes Cas9.

37 . The compositions of claim 36 , wherein the modification is in the region corresponding to amino acids 1105-1138 of a Streptococcus pyogenes Cas9.

38 . The compositions of claim 27 , wherein the modification is in the region corresponding to amino acids 718-757 of a Streptococcus pyogenes Cas9.

39 . The composition of claim 27 , wherein the modification is an inserted nuclease domain or an inserted RNA binding domain.

40 . The composition of claim 39 , wherein the inserted RNA binding domain is Csy4.

Assignees

• Caribou Biosciences Inc

Inventors

• May Andrew Paul
• Haurwitz Rachel E
• Doudna Jennifer A
• Berger James M
• Carter Matthew Merrill
• Donohoue Paul

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P35/00

  Antineoplastic agents · CPC title